(ABBV) AbbVie - NYSE
Sector: Healthcare | Industry: Drug Manufacturers - General | Exchange: NYSE (USA) | Market Cap: 390.868m USD | Total Return: 31.9% in 12m
Avg Turnover: 1.26B
EPS Trend: -86.8%
Qual. Beats: 0
Rev. Trend: 88.2%
Qual. Beats: 0
Warnings
P/E ratio 107.9
Altman Z'' -0.45 < 1.0 - financial distress zone
Choppy
Tailwinds
No distinct edge detected
AbbVie Inc. is a global biopharmaceutical company focused on the research, development, and commercialization of specialized medicines. Its portfolio spans several high-growth therapeutic areas, including immunology, oncology, aesthetics, neuroscience, and eye care. Key products include Skyrizi and Rinvoq for inflammatory conditions, Vraylar for psychiatric disorders, and the Botox franchise for both cosmetic and therapeutic applications.
The company operates within the biotechnology sector, where business models rely heavily on patent protection and a robust research pipeline to offset the eventual loss of exclusivity on legacy blockbuster drugs. AbbVies strategy involves diversifying its revenue streams through strategic acquisitions and internal development to mitigate the impact of biosimilar competition. You can further evaluate these pipeline developments and valuation metrics on ValueRay.
Headquartered in North Chicago, Illinois, AbbVie maintains a global manufacturing and distribution infrastructure to support its diverse product lines. The companys reach extends to specialized treatments for chronic conditions such as hepatitis C, Parkinsons disease, and advanced glaucoma.
- Skyrizi and Rinvoq sales growth offsets Humira biosimilar revenue erosion
- Aesthetics portfolio recovery hinges on resilient high-end consumer discretionary spending
- Oncology pipeline expansion through ImmunoGen acquisition diversifies long-term revenue streams
- Medicare drug price negotiations pose systemic risk to immunology and oncology margins
- Strategic R&D investment in neuroscience assets targets multi-billion dollar migraine market
| Net Income: 3.64b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.15 > 0.02 and ΔFCF/TA 3.99 > 1.0 |
| NWC/Revenue: -13.64% < 20% (prev -15.21%; Δ 1.57% < -1%) |
| CFO/TA 0.16 > 3% & CFO 21.2b > Net Income 3.64b |
| Net Debt (63.5b) to EBITDA (16.9b): 3.75 < 3 |
| Current Ratio: 0.80 > 1.5 & < 3 |
| Outstanding Shares: last quarter (1.77b) vs 12m ago 0.11% < -2% |
| Gross Margin: 70.68% > 18% (prev 70.69%; Δ -0.02% > 0.5%) |
| Asset Turnover: 46.08% > 50% (prev 42.13%; Δ 3.95% > 0%) |
| Interest Coverage Ratio: 3.05 > 6 (EBIT TTM 8.88b / Interest Expense TTM 2.91b) |
| A: -0.06 (Total Current Assets 33.5b - Total Current Liabilities 42.1b) / Total Assets 136b |
| B: -0.13 (Retained Earnings -17.9b / Total Assets 136b) |
| C: 0.07 (EBIT TTM 8.88b / Avg Total Assets 136b) |
| D: -0.05 (Book Value of Equity -6.61b / Total Liabilities 143b) |
| Altman-Z'' = -0.45 = B |
| DSRI: 0.91 (Receivables 12.5b/12.5b, Revenue 62.8b/57.4b) |
| GMI: 1.00 (GM 70.69% / 70.68%) |
| AQI: 0.94 (AQ_t 0.71 / AQ_t-1 0.76) |
| SGI: 1.10 (Revenue 62.8b / 57.4b) |
| TATA: -0.13 (NI 3.64b - CFO 21.2b) / TA 136b) |
| Beneish M = -3.08 (Cap -4..+1) = AA |
As of June 24, 2026, the stock is trading at USD 234.76 with a total of 7,182,895 shares traded. Over the past week, the price has changed by +5.94%, over one month by +10.15%, over three months by +15.51% and over the past year by +31.92%.
Current recommended Stop Loss: 227.40 (which is 3.1% or 1.2 ATR below the current price).
AbbVie has received a consensus analysts rating of 4.00. Therefore, it is recommended to buy ABBV.
- StrongBuy: 12
- Buy: 4
- Hold: 12
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 253.6 | 8% |
P/E Trailing = 107.9171
P/E Forward = 15.1976
P/S = 6.0888
P/B = 50.4573
P/EG = 0.5967
Revenue TTM = 62.8b USD
EBIT TTM = 8.88b USD
EBITDA TTM = 16.9b USD
Long Term Debt = 64.5b USD (from longTermDebt, last quarter)
Short Term Debt = 8.33b USD (from shortTermDebt, last quarter)
Debt = 72.9b USD (from shortLongTermDebtTotal, last quarter)
Net Debt = 63.5b USD (calculated: Debt 72.9b - CCE 9.39b)
Enterprise Value = 454b USD (391b + Debt 72.9b - CCE 9.39b)
Interest Coverage Ratio = 3.05 (Ebit TTM 8.88b / Interest Expense TTM 2.91b)
EV/FCF = 21.77x (Enterprise Value 454b / FCF TTM 20.9b)
FCF Yield = 4.59% (FCF TTM 20.9b / Enterprise Value 454b)
FCF Margin = 33.21% (FCF TTM 20.9b / Revenue TTM 62.8b)
Net Margin = 5.79% (Net Income TTM 3.64b / Revenue TTM 62.8b)
Gross Margin = 70.68% ((Revenue TTM 62.8b - Cost of Revenue TTM 18.4b) / Revenue TTM)
Gross Margin QoQ = 71.88% (prev 72.61%)
Tobins Q-Ratio = 3.33 (Enterprise Value 454b / Total Assets 136b)
Interest Expense / Debt = 3.99% (Interest Expense 2.91b / Debt 72.9b)
Taxrate = 39.06% (2.33b / 5.97b)
NOPAT = 5.41b (EBIT 8.88b * (1 - 39.06%))
Current Ratio = 0.80 (Total Current Assets 33.5b / Total Current Liabilities 42.1b)
Debt / Equity = -11.02 (negative equity) (Debt 72.9b / totalStockholderEquity, last quarter -6.61b)
Debt / EBITDA = 3.75 (Net Debt 63.5b / EBITDA 16.9b)
Debt / FCF = 3.04 (Net Debt 63.5b / FCF TTM 20.9b)
Total Stockholder Equity = -3.14b (last 4 quarters mean from totalStockholderEquity)
RoA = 2.67% (Net Income 3.64b / Total Assets 136b)
RoE = -115.7% (negative equity) (Net Income TTM 3.64b / Total Stockholder Equity -3.14b)
RoCE = 14.47% (EBIT 8.88b / Capital Employed (Equity -3.14b + L.T.Debt 64.5b))
RoIC = 5.44% (NOPAT 5.41b / Invested Capital 99.5b)
WACC = 6.02% (E(391b)/V(464b) * Re(6.69%) + D(72.9b)/V(464b) * Rd(3.99%) * (1-Tc(0.39)))
Discount Rate = 6.69% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 38.92 | Cagr: 0.05%
[DCF] Terminal Value 77.97% ; FCFF base≈18.7b ; Y1≈21.4b ; Y5≈31.5b
[DCF] Fair Price = 232.4 (EV 474b - Net Debt 63.5b = Equity 411b / Shares 1.77b; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: -86.78 | EPS CAGR: -7.31% | SUE: -0.66 | # QB: 0
Revenue Correlation: 88.25 | Revenue CAGR: 4.78% | SUE: 0.63 | # QB: 0
EPS current Quarter (2026-06-30): EPS=3.77 | Chg30d=+0.10% | Revisions=+14% | Analysts=21
EPS next Quarter (2026-09-30): EPS=3.85 | Chg30d=+0.02% | Revisions=+37% | Analysts=21
EPS current Year (2026-12-31): EPS=14.24 | Chg30d=+0.03% | Revisions=-23% | GrowthEPS=+42.4% | GrowthRev=+9.9%
EPS next Year (2027-12-31): EPS=16.25 | Chg30d=+0.09% | Revisions=+33% | GrowthEPS=+14.1% | GrowthRev=+8.2%
[Analyst] Revisions Ratio: +37%